STANLEY R HAMILTON to Proto-Oncogene Proteins p21(ras)
This is a "connection" page, showing publications STANLEY R HAMILTON has written about Proto-Oncogene Proteins p21(ras).
Connection Strength
0.141
-
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res. 2008 May 01; 14(9):2560-9.
Score: 0.050
-
Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. Clin Cancer Res. 2021 01 01; 27(1):52-59.
Score: 0.030
-
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85.
Score: 0.021
-
MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol. 2013 Jan; 229(1):99-110.
Score: 0.017
-
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6.
Score: 0.013
-
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005 Sep 21; 97(18):1330-8.
Score: 0.010